SM
KPTI icon

SG3 Management’s Karyopharm Therapeutics KPTI Stock Holding History

SG3 Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,667
Closed -$184K – 620
2022
Q1 		$184K Buy
+1,667
New +$208K 0.01% 773
2020
Q3 		– Sell
-1,000
Closed -$284K – 983
2020
Q2 		$284K Buy
+1,000
New +$296K 0.02% 447

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

SG3 Management's KPTI Position: Q4 2021 in Review

SG3 Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2021, closing a stake of 1,667 shares — an estimated $166K sold.

SG3 Management first reported a position in KPTI in Q2 2020 and held it in 2 quarters. The position peaked at $146K in Q3 2021. 143 funds tracked by Wall St. Rank hold KPTI as of Q4 2021.

  • SG3 Management reported no remaining Karyopharm Therapeutics position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 1,667 Karyopharm Therapeutics shares in Q4 2021, an estimated $166K.
  • SG3 Management first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 2 quarters.
  • SG3 Management's Karyopharm Therapeutics position peaked at $146K in Q3 2021.
  • 143 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.